Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 488 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diphenhydramine (Benadryl) Clear all
Completed Phase 2 Interventional Results available

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

NCT00618826
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 13, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT03107182
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
Drug · Procedure · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 13, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

NCT05285813
View directory record Official record
Conditions
AML, MDS
Interventions
Vibecotamab, Dexamethasone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Terminated Not applicable Interventional

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

NCT00000875
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Diphenhydramine hydrochloride, Lymphocytes, Activated, Lamivudine, Zidovudine, Acetaminophen, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 13, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Repeat Dosing of Psilocybin in Migraine Headache

NCT04218539
View directory record Official record
Conditions
Migraine Headache
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Treatment for Sleep Disturbance in Orthopaedic Trauma Patients

NCT03779243
View directory record Official record
Conditions
Sleep Disturbance, Trauma
Interventions
Melatonin 5mg and Sleep Education, Placebo
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 13, 2026, 9:02 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

NCT05244460
View directory record Official record
Conditions
Cannabis Hyperemesis Syndrome
Interventions
Droperidol Injectable Product, Diphenhydramine
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Austintown, Ohio • Boardman, Ohio • Warren, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

NCT04189588
View directory record Official record
Conditions
Oncology Patients Receiving Chemotherapy
Interventions
Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery

NCT01510379
View directory record Official record
Conditions
Nausea and Vomiting Post-foregut Surgery
Interventions
Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, IV promethazine 25 mg q 6 hours prn, Elixir promethazine 25 mg q 6 hours prn after discharge
Device · Drug
Lead sponsor
Kyle A Perry
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 3 Interventional

Prevention of Kidney Transplant Rejection

NCT00005010
View directory record Official record
Conditions
End-Stage Renal Disease, Chronic Allograft Nephropathy
Interventions
Irbesartan, Pravastatin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

NCT01852942
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

NCT01411410
View directory record Official record
Conditions
Neoplasms
Interventions
Paclitaxel, Copanlisib (BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
St Louis, Missouri • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

NCT02676466
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo)
Dietary Supplement · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
70 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 13, 2026, 9:02 PM EDT
Terminated Not applicable Interventional Results available

Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia

NCT01230788
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia, ALL
Interventions
rituximab
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Atlanta, Georgia • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Oct 13, 2026, 9:02 PM EDT
Withdrawn Phase 4 Interventional

Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty

NCT06333522
View directory record Official record
Conditions
Arthrofibrosis of Knee
Interventions
Losartan
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2Phase 3 Interventional

Risk Reduction for Alzheimer's Disease

NCT02913664
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions
Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 13, 2026, 9:02 PM EDT
Withdrawn Not applicable Interventional

Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department

NCT00573599
View directory record Official record
Conditions
Acute Migraine Headache
Interventions
prochlorperazine and benadryl IV, Imitrex SubQ, saline IV
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 13, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT05896228
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast
Drug
Lead sponsor
Benjamin T Diamond, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Not listed Phase 2 Interventional

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

NCT04308837
View directory record Official record
Conditions
Gastric Cancer, Stomach Cancer
Interventions
Paclitaxel, Carboplatin, Dexamethasone, Diphenhydramine, Famotidine, Palonosetron, 3D conformal or intensity modulated radiotherapy, Surgical resection, Adjuvant Chemotherapy
Drug · Radiation · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 13, 2026, 9:02 PM EDT